These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 9181646)
1. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection. The Alter Study. Nordic HIV Therapy Group. Gerstoft J; Melander H; Bruun JN; Pedersen C; Głtzsche PC; Berglund O; Mathiesen L; Skinhłj P; Norrby SR Scand J Infect Dis; 1997; 29(2):121-8. PubMed ID: 9181646 [TBL] [Abstract][Full Text] [Related]
2. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213 [TBL] [Abstract][Full Text] [Related]
3. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group. Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767 [TBL] [Abstract][Full Text] [Related]
5. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients. Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM; Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874 [TBL] [Abstract][Full Text] [Related]
6. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups. Ragni MV; Amato DA; LoFaro ML; DeGruttola V; Van Der Horst C; Eyster ME; Kessler CM; Gjerset GF; Ho M; Parenti DM Blood; 1995 May; 85(9):2337-46. PubMed ID: 7727768 [TBL] [Abstract][Full Text] [Related]
7. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E; Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872 [TBL] [Abstract][Full Text] [Related]
8. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine. Marchisio P; Principi N; Gabiano C; Galli L; Gattinara GC; Caselli D; Zuccotti G; La Regina A; Paga C Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266 [TBL] [Abstract][Full Text] [Related]
9. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038 [TBL] [Abstract][Full Text] [Related]
10. Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV. Mauss S; Adams O; Willers R; Jablonowski H J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):469-77. PubMed ID: 8605592 [TBL] [Abstract][Full Text] [Related]
11. Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection. Husson RN; Mueller BU; Farley M; Woods L; Kovacs A; Goldsmith JC; Ono J; Lewis LL; Balis FM; Brouwers P Pediatrics; 1994 Feb; 93(2):316-22. PubMed ID: 7907174 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Collier AC; Coombs RW; Fischl MA; Skolnik PR; Northfelt D; Boutin P; Hooper CJ; Kaplan LD; Volberding PA; Davis LG; Henrard DR; Weller S; Corey L Ann Intern Med; 1993 Oct; 119(8):786-93. PubMed ID: 8379600 [TBL] [Abstract][Full Text] [Related]
13. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849 [TBL] [Abstract][Full Text] [Related]
14. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. Yarchoan R; Lietzau JA; Nguyen BY; Brawley OW; Pluda JM; Saville MW; Wyvill KM; Steinberg SM; Agbaria R; Mitsuya H J Infect Dis; 1994 Jan; 169(1):9-17. PubMed ID: 7903976 [TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine. Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia. Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263 [No Abstract] [Full Text] [Related]
17. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection. Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645 [TBL] [Abstract][Full Text] [Related]
18. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group. Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; Smaldone L; Wainberg MA Ann Intern Med; 1995 Oct; 123(8):561-71. PubMed ID: 7677296 [TBL] [Abstract][Full Text] [Related]
19. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients]. Reynes J; Montes B; Delmas B; Vendrell JP; Janbon F; Segondy M Pathol Biol (Paris); 1997 May; 45(5):441-4. PubMed ID: 9296101 [TBL] [Abstract][Full Text] [Related]
20. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. Dolin R; Amato DA; Fischl MA; Pettinelli C; Beltangady M; Liou SH; Brown MJ; Cross AP; Hirsch MS; Hardy WD Arch Intern Med; 1995 May; 155(9):961-74. PubMed ID: 7726705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]